Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Status Completed

Clinical Trial Summary

Tanreqing Injection is widely used in respiratory disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. This study record clinical use of Tanreqing Injection in the real world, observe the adverse drug reactions/ adverse drug events during treatment, and figure out why Tanreqing induced severe allergic reaction happens.

Clinical Trial Description

As a compound traditional Chinese medicine, Tanreqing Injection was approved by China Food and Drug Administration(CFDA) in 2003, and widely used respiratory disease, such as biofilm related upper respiratory infections, pneumonia and bronchitis. During its 11 years marketing in China, there was hardly any serious adverse drug reactions except for a few cases reported as severe allergic reaction. In this study, clinical pharmacists in selected hospitals will not only record the clinical use and the adverse drug reactions/ adverse drug events of this injection, but also try to figure out why drug-induced severe allergic reaction happens through a nested case-control study. This real world study for Tanreqing Injection with 30400 patients will be conducted from January.2014 to June.2016. ;

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

Adverse Drug Reaction
Drug Allergy
Drug-Related Side Effects and Adverse Reactions

Clinical Trial Details

NCT number	NCT02094638
Study type	Observational [Patient Registry]
Source	Peking University Third Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 2014

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT02559960` - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed	`NCT01946919` - Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Recruiting	`NCT04154553` - Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Completed	`NCT01732302` - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients	N/A
Completed	`NCT05224804` - Pharmacists' Knowledge and Attitudes About ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals
Completed	`NCT02297126` - A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program	N/A
Completed	`NCT03093818` - PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions	N/A
Not yet recruiting	`NCT04568668` - Evaluating ActionADE in Reducing Adverse Drug Reactions	N/A
Recruiting	`NCT02012504` - Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients	Phase 0
Completed	`NCT01872520` - Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study	N/A
Completed	`NCT01467050` - Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients	Phase 4
Completed	`NCT01679964` - Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study	Phase 4
Recruiting	`NCT01906710` - the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes	N/A
Completed	`NCT02888834` - Serious Adverse Drug Reaction and Their Preventability	N/A
Completed	`NCT02838212` - Adverse Drug Reactions With Fatal Outcome	N/A
Completed	`NCT02159209` - The Drug Induced Renal Injury Consortium	N/A
Completed	`NCT02134587` - Educational Intervention in Pharmacovigilance for Hospital Health Professionals	N/A
Completed	`NCT04553107` - Reducing Costs by Deprescribing Medications	N/A
Recruiting	`NCT06219720` - The Texas Interprofessional Pharmacogenomics (IPGx)
Recruiting	`NCT05508763` - Personalised Therapeutics @LUMC